Page 3 - Pharma Sector News Today

Sun Pharmaceutical Industries plans to acquire all outstanding shares of Taro Pharmaceutical Industries for $43 per share in cash, aiming to gain complete control over its subsidiary

In 2012, a parliamentary standing committee of the health ministry had observed in its report that some of the state licensing authorities issued manufacturing licences for a large number of FDCs without prior clearance from the central drug authority, resulting in the availability of several FDCs which were not tested for safety and efficacy.

Milind Karmarkar says: “In mid and especially smallcaps, there are excesses. It may continue for a long time, because I have learned that during the software boom, when you think there are excesses, the market, the prices can grow four times from there. As a fund manager, I would not get into that at all.”

Nithya Balasubramanian says: “At a top-down level, there is a lot more growth than what we are seeing in data. But I believe that the growth drivers will possibly shift into volume growth from pricing growth. The last two years have been pretty good in terms of pricing growth because of the higher inflation as well which was passed along.”

“For one week or so, probably the market could be range-bound or and there is scope for some profit booking at this point. So, I am not very bullish, although the trend is going up but with less momentum. So there is some scope for profit booking. I do not see a lot of upside at this moment. I would be a little neutral at this point in time.”

Sumeet Bagadia of Choice Broking has chosen Torrent Pharma as his ‘Christmas 2023 Pick’. Bagadia has recommended a ‘Buy’ on the pharma stock at ₹2,185 and up to ₹2,090 for a target price of ₹2,420 to ₹2,490.

Fleming is a backward integrated API manufacturer with global leadership in select muscle relaxant, anti-arthritis, and antihistamine APIs with two regulatory-approved manufacturing units. The company sells to customers in over 65 countries across Latin America, Europe, Asia, and MENA.

The domestic pharmas growth of 3.5 percent is the lowest monthly growth this year as a slowdown was seen across all key therapies

In a recent meeting held by the drug controller on global clinical trials, the OPPI sought from the government a notification system through the drug regulatory authoritys digital portal-SUGAM. It has asked for linking of the SUGAM Portal at Centre and state levels and, then, making public the non-commercial information in respect of the filed/pending applications and the approvals granted, it said.

Shares of Dr Reddys Laboratories (DRL) shed almost 7 percent in trade on Monday after the US Food and Drug Administration (USFDA) issued three observations for the companys Telangana plant.